Point-Counterpoint: Deep Dive into CLL/SLL: Management of Newly Diagnosed and Refractory Disease
Released On
May 8, 2025
Expires On
May 8, 2026
Media Type
Internet
Completion Time
30 minutes
Specialty
Hematology-Oncology, Pathology, Pharmacy
Topic(s)
Leukemia, Oncology
Educational Provider
This activity is provided by USF Health in partnership with Paradigm Medical Communications, LLC., Moffitt Cancer Center, CLL Society and HealthTree Foundation.
Supporter Acknowledgement
This activity is funded by an independent medical education grant from AbbVie, Inc.
Credit Available
- Physicians - maximum of 0.5 AMA PRA Category 1 Credit™
- Nurse Practitioners - may claim a maximum of 0.5 Category 1 Credit for completing this activity
- Physician Assistants - may claim a maximum of 0.5 Category 1 Credit for completing this activity
- Nurses - may claim a maximum of 0.5 ANCC pharmacotherapeutic contact hour
- Pharmacists - maximum of 0.5 contact hour (0.05 CEU)
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity has been designed to address the educational needs of community- and academic-based hematologists/oncologists, medical oncologists, hematologists, advanced oncology certified nurse practitioners, oncology PAs, oncology nurses, oncology pharmacists, and may be of interest to pathologists and other healthcare providers who manage patients with chronic lymphocytic leukemia (CLL).
Program Overview
Treatment of CLL/small lymphocytic lymphoma (SLL) often begins with a period of observation. Therapy depends on signs and symptoms, as well as the patient’s quality of life. First- and second-line treatment selection depends on multiple factors; however, many oncology and/or hematology clinicians are challenged to determine when to initiate treatment or when to conduct cytogenetic and molecular testing. Patient management is complex, and will be highlighted and discussed in this activity for oncology and hematology clinicians who care for patients with CLL/SLL.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Determine when to initiate first-line treatment of CLL/SLL according to disease signs and symptoms and patients’ preferences
- Assess first-line treatment regimens for CLL/SLL, including mechanisms of action, efficacy data, and safety profiles
- Individualize treatment strategies for patients with CLL/SLL, including first- and second-line treatment, according to patient- and disease-related characteristics, such as prognostic variables, comorbidities, and minimal residual disease, as well as patients’ preferences for fixed-duration or continuous treatment
Faculty
Maen Hussein, MD
President, Florida Society of Clinical Oncology
Assistant Professor
University of Central Florida College of Medicine
Orlando, FL
Nitin Jain, MD
Professor
Department of Leukemia
Director, Leukemia CAR-T Program
The University of Texas MD Anderson Cancer Center
Houston, TX
Accreditations
Physicians
USF Health designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS)–European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician assistants may claim a maximum of 0.5 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credits™ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 0.5 contact hour may be earned by learners who successfully complete this continuing nursing education activity. USF Health, the accredited provider, acknowledges Paradigm Medical Communications, LLC as the partner in the planning and execution of this CNE activity.
This activity is awarded 0.5 ANCC pharmacotherapeutic contact hour.
Pharmacists
USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 0.5 contact hour (0.05 CEU). Universal program number is as follows: 0230-9999-25-008-H01-P.
Date of original release: May 8, 2025. Date credit expires: May 8, 2026.
Disclosure of Relevant Financial Relationships
USF Health adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below.
FacultyMaen Hussein, MD
Consultant fees: Abbvie; Aptitude Health; BeiGene; Ipsen Therapeutics; Mirati Therapeutics; Oncocyte AstraZeneca; Bristol Myers Squibb; Coherus BioSciences; CTI BioPharma Corp; Exelixis; G1 Therapeutics; Integra Connect; Karyopharm (relationships ended)
Nitin Jain, MD
Grants/research support: AbbVie; Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BMS; Carna Biosciences; Cellectis; Dialectic Therapeutics; Fate Therapeutics; Genentech; Kisoji Biotechnology; Kite/Gilead; Loxo Oncology; Medisix; Mingsight Pharmaceuticals; Newave Pharmaceutical; Novalgen; Novartis; Pfizer; Pharmacyclics; Precision Biosciences; Sana Biotechnology; Takeda
Advisory board or panel fees: AbbVie; Adaptive Biotechnologies; AstraZeneca; Autolus; Beigene; Bristol Myers Squibb; CareDX; Cellectis; Genentech; Ipsen; Janssen; Kite/Gilead; MEI Pharma; MingSight Pharmaceuticals; Novalgen; Pharmacyclics; Precision Biosciences
Content Reviewers
Christy Thai, PharmD, BCPS has no financial interests/relationships or affiliations in relation to this activity.
Danielle Walker, DNP, APRN, AGNP-C has no financial interests/relationships or affiliations in relation to this activity.
Staff
USF Health Office of Continuing Professional Development and Paradigm Medical Communications, LLC staff have no relevant financial interests/relationships or affiliations in relation to this activity.
CLL Society Reviewer
Brian Koffman, MDCM (retired), MSed
Consultant fees: AbbVie; BeiGene; Biomea Fusion; Bristol Myers Squibb; Johnson & Johnson; Lilly
Honoraria: AstraZeneca; Bristol Myers Squibb; Genmab; Invivyd; Nurix
Stock/shareholder (self-managed): AbbVie; AstraZeneca; Biomea Fusion; Bristol Myers Squibb; Invivyd; Johnson & Johnson; Merck; Nurix; Pfizer; Vincerx Pharma; Vaxart
Instructions for Participation and Credit
To receive a certificate of participation, participants must:
- Follow instructions to register or log in with your professional information and complete the pretest
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
For questions regarding CME credit, please contact [email protected].
There are no fees for participating in this activity.
Course Viewing Requirements
Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader.
Technical Support
If you have any technical problems or playback issues, please email [email protected].
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
The information provided by this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.
USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center, and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CE to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.
Disclaimer
This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, USF Health and Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As ACCME-accredited providers, USF Health and Paradigm Medical Communications, LLC must ensure that their activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by USF Health and Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, USF Health and Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by USF Health and Paradigm Medical Communications, LLC. USF Health and Paradigm Medical Communications, LLC accept no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Information
If you have any questions or comments, please email us at [email protected].
© 2025 USF Health and Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of USF Health and Paradigm Medical Communications, LLC.